Benzinga | Jan 28, 2022 08:09AM EST

Truist Securities Initiates Coverage On Corcept Therapeutics with Buy Rating, Announces Price Target of $30

Truist Securities analyst Gregory Fraser initiates coverage on Corcept Therapeutics (NASDAQ:CORT) with a Buy rating and announces Price Target of $30.